Evidence map›Paper›PMID 40425765›Full record

ArticleNaunyn-Schmiedeberg's archives of pharmacology2025

ML385 increases ferroptosis via inhibiting Nrf2/HO-1 pathway to enhances the sensitivity of MCF-7 TAMR to tamoxifen.

Jie Yuan, Wenjun Huang, Minxia Lin, Shishen Sun, Fei Zhong, Lei Ye, Hao Yin, Xiaowei Ou, Zhiqiang Zeng

Abstract read
PubMed Publisher
In one paragraph

Article in Naunyn-Schmiedeberg's archives of pharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Review
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Jie Yuan *Department of General Surgery, Foshan Fosun Chancheng Hospital, Foshan, China. candlewjy@163.com.
Wenjun Huang *Department of General Surgery, Foshan Fosun Chancheng Hospital, Foshan, China.
Minxia LinFoshan Clinical Medical School, Guangzhou University of Chinese Medicine, Foshan, China.
Shishen SunFoshan Clinical Medical School, Guangzhou University of Chinese Medicine, Foshan, China.
Fei ZhongFoshan Clinical Medical School, Guangzhou University of Chinese Medicine, Foshan, China.
Lei YeFoshan Clinical Medical School, Guangzhou University of Chinese Medicine, Foshan, China.
Hao YinFoshan Municipal Key Laboratory of Precision Oncology, Foshan Fosun Chancheng Hospital, Foshan, China.
Xiaowei OuDepartment of General Surgery, Foshan Fosun Chancheng Hospital, Foshan, China.
Zhiqiang ZengDepartment of General Surgery, Foshan Fosun Chancheng Hospital, Foshan, China. zengzhiqiang@fsccyy.com.

Funding

Dongping talent plan of Foshan Fosun Chancheng Hospital 047Guangdong Basic and Applied Basic Research Foundation 2021A1515220130Self-funded science and technology innovation projects of Foshan 2220001004110 and 2220001004079
6 · The paper itself

Abstract

The purpose of this study was to study the mechanism of the increased sensitivity of breast cancer tamoxifen-resistant strains by enhancing ferroptosis. CCK-8 and colony formation were used to detect cell proliferation. Ferroptosis indicator reactive oxygen species (ROS), glutathione (GSH) activity, ATP activity, Fe

Indexed as

Antineoplastic Agents, HormonalBreast NeoplasmsFerroptosisHeme Oxygenase-1NF-E2-Related Factor 2TamoxifenAcetamidesAnimalsBenzodioxolesCell ProliferationDrug Resistance, NeoplasmFemaleHumansMCF-7 CellsMiceMice, Inbred BALB CAcetamidesAntineoplastic Agents, HormonalBenzodioxolesHeme Oxygenase-1HMOX1 protein, humanML385NFE2L2 protein, humanNF-E2-Related Factor 2Reactive Oxygen SpeciesTamoxifenML385Nrf2/HO-1 pathwayTamoxifen

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.